Clene is a clinical-stage pharmaceutical company focusing on the discovery, development, and commercialization of clean-surfaced nanotechnology therapeutics. Co. is focused on addressing the unmet medical needs in two areas: first, those related to central nervous system disorders including Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease; and second, those related to COVID-19, an infectious viral respiratory disease with serious and sometimes fatal co-morbidities. In addition to the development of clean-surfaced nanocrystals, Co.'s electro-crystal-chemistry platform can produce ionic solutions of various transition elements including silver, zinc, and others. The CLNN average annual return since 2018 is shown above.
The Average Annual Return on the CLNN average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CLNN average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CLNN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free CLNN Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
